Two Sigma Securities’s Ultragenyx Pharmaceutical RARE Stock Holding History

Two Sigma Securities’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,875	Closed	-$327K	–	1917
2025 Q3	$327K	Buy	+10,875	New	+$326K	0.05%	540
2021 Q3	–	Sell	-2,139	Closed	-$204K	–	1870
2021 Q2	$204K	Buy	+2,139	New	+$223K	0.01%	1278
2019 Q1	–	Sell	-4,802	Closed	-$209K	–	2329
2018 Q4	$209K	Buy	+4,802	New	+$262K	﹤0.01%	1688
2017 Q3	–	Sell	-3,922	Closed	-$244K	–	1170
2017 Q2	$244K	Buy	+3,922	New	+$236K	0.05%	444

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Securities's RARE Position: Q4 2025 in Review

Two Sigma Securities sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 10,875 shares — an estimated $327K sold.

Two Sigma Securities first reported a position in RARE in Q2 2017 and held it in 4 quarters. The position peaked at $327K in Q3 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Two Sigma Securities reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Two Sigma Securities sold 10,875 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $327K.
Two Sigma Securities first reported a position in Ultragenyx Pharmaceutical in Q2 2017 and held it in 4 quarters.
Two Sigma Securities's Ultragenyx Pharmaceutical position peaked at $327K in Q3 2025.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.